IN8BIO, Inc.
Biotechnology company · New York, United States · Nasdaq: INAB
IN8BIO, Inc. is a biotechnology company headquartered in New York, United States. Its earliest recorded incorporation is in 2018. Its shares trade on Nasdaq under the ticker INAB. It has reported private securities offerings to the US SEC, most recently $20 million sold in a notice filed in 2025.
IN8BIO at a glance
What does IN8BIO do?
Private fundraising reported to the SEC
6 Form D notices; the most recent reported $20.1 million sold (2025).
Frequently asked questions about IN8BIO
Where is IN8BIO headquartered?
IN8BIO, Inc. is headquartered in New York, United States.
What does IN8BIO do?
IN8BIO, Inc. is a biotechnology company. Its SEC industry classification is Biological Products, (No Diagnostic Substances).
Is IN8BIO a public company?
Yes. IN8BIO, Inc. trades on Nasdaq under the ticker INAB.
When was IN8BIO founded?
The earliest incorporation on record for IN8BIO, Inc. is in 2018, according to public company registers.
Similar companies
- Lexeo Therapeutics, Inc.New York City, New York, United States
- MiNK Therapeutics, Inc.New York City, New York, United States
- Anavex Life Sciences Corp.New York City, New York, United States
- Brainstorm Cell Therapeutics Inc.New York City, New York, United States
- Bioincept LLCNew York City, New York, United States
- Protara Therapeutics, Inc.New York City, New York, United States
- Ancilia Biosciences, Inc.New York City, New York, United States
- Microstructure Imaging, Inc.New York City, New York, United States
Need a CRO or CDMO for your next study?
Compare transparent quotes from research and manufacturing partners, then contract once. Free for buyers.
Compare quotesSources
Location data: GeoNames (geonames.org), CC BY 4.0.
Last updated 2026-09-23.